Common Models, Different Approaches

Drug Safety

Volumn 38, Issue 8, 2015, Pages 683-686

  Gagne, Joshua J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; INDOMETACIN; KETOROLAC; VALPROIC ACID;

ACUTE HEART INFARCTION; COMMON DATA MODEL; DATA BASE; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECOSYSTEM; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HIP FRACTURE; HUMAN; LIVER INJURY; MODEL; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PRODUCT SAFETY; PROPENSITY SCORE; STATISTICAL SIGNIFICANCE; TOXIC HEPATITIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTRONIC HEALTH RECORD; FACTUAL DATABASE; POSTMARKETING SURVEILLANCE; SENTINEL SURVEILLANCE; STATISTICS AND NUMERICAL DATA;

DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTRONIC HEALTH RECORDS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; SENTINEL SURVEILLANCE;

EID: 84938198769     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0313-9     Document Type: Editorial

References (9)

1. Platt R, Carnahan RM, Brown JS, et al. The US Food and Drug Administration’s Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):1–8.
2. Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design of the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153:600–6.
3. Suissa S, Henry D, Caetano P, et al. CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med. 2012;6:134–40.
4. Andersen M, Bergman U, Choi NK, et al. The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia. Pharmacoepidemiol Drug Saf. 2013;22:700–4.
5. Coloma PM, Schuemie MJ, Trifiro G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011;20:1–11.
6. Curtis LH, Weiner MG, Boudreau DM, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):23–31.
7. Overhage JM, Ryan PB, Reich CG, Hartema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54–60.
8. Xu Y, Zhou X, Suehs BT, et al. A comparative assessment of Observational Medical Outcomes Partnership and Mini-Sentinel common data models and analytics: implications for active drug safety surveillance. Drug Saf 2015 (this issue). doi:10.1007/s40264-015-0297-5.
9. Coronel-Moreno C, Vilk Y, Silva I, Yih K, Kulldorff M. Mini-Sentinel Prospective Routine Observational Monitoring Program Tool: continuous and group sequential analysis with self-control design. Technical Users’ Guide version: 1.0. Available at: http://www.mini-sentinel.org/work_products/Statistical_Methods/Mini-Sentinel_PROMPT_Self-Control-Design-Tool_Technical-Users-Guide.pdf. Accessed 8 June 2015.